Home>
US Stocks>
Perspective Therapeutics

Perspective Therapeutics share price today

(CATX)

Perspective Therapeutics share price is $3.25 & ₹276.89 as on 25 Dec 2024, 2.30 'hrs' IST

$3.25

▲

0.11

(3.5%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Perspective Therapeutics share price in Dollar and Rupees. Guide to invest in Perspective Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Perspective Therapeutics. Get details on the Indian mutual funds that are investing in Perspective Therapeutics. Get Analyst recommendations and forecasts along with all the Perspective Therapeutics's financials.

Perspective Therapeutics share price movements

Today's Low: $3.10
Today's High: $3.28
$3.25
4.62%
Downside
Day's Volatility :5.44%
Upside
0.87%
52 Weeks Low: $2.70
52 Weeks High: $19.05
$3.25
16.92%
Downside
52 Weeks Volatility :85.83%
Upside
82.94%

Perspective Therapeutics Returns

Period	Perspective Therapeutics Inc.	Index (Russel 2000)
3 Months	-73.49%	0.0%
6 Months	-67.07%	0.0%
1 Year	-31.55%	0.0%
3 Years	-14.47%	-21.1%

Perspective Therapeutics Key Statistics

in dollars & INR

Previous Close	$3.14
Open	$3.19
Today's High	$3.2785
Today's Low	$3.1
Market Capitalization	$219.7M
Today's Volume	$502.6K
52 Week High	$19.05
52 Week Low	$2.7
Revenue TTM	$1.6M
EBITDA	$-55.8M
Earnings Per Share (EPS)	$-1.33
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-27.02%

How to invest in Perspective Therapeutics from India?

It is very easy for Indian residents to invest directly in Perspective Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Perspective Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Perspective Therapeutics or CATX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Perspective Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Perspective Therapeutics shares which would translate to 0.262 fractional shares of Perspective Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Perspective Therapeutics, in just a few clicks!

Returns in Perspective Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Perspective Therapeutics investment value today

Current value as on today

₹70,660

Returns

₹29,340

(-29.34%)

Returns from Perspective Therapeutics Stock

₹31,579 (-31.58%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Perspective Therapeutics

-19.64%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Investment in Perspective Therapeutics from India has reduced in the last 30 days as on Dec 26, 2024. -19.64% less purchase transactions for Perspective Therapeutics in the last 30 days versus the previous period.

86%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Perspective Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 86% more investors are searching Perspective Therapeutics in the last 30 days versus the previous period.

Analyst Recommendation on Perspective Therapeutics

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Perspective Therapeutics(by analysts ranked 0 to 5 stars)

Based on 8 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Perspective Therapeutics

What analysts predicted

Upside of 396.92%

Current:

$3.25

Target:

$16.15

Insights on Perspective Therapeutics

Price Movement
In the last 7 days, CATX stock has moved up by 14.4%
Decreasing Revenue
Revenue is down for the last 2 quarters, 1.90M → 337.0K (in $), with an average decrease of 82.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -11.70M → -15.12M (in $), with an average decrease of 29.2% per quarter
CATX vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 62.7% return, outperforming this stock by 86.3%
Price to Sales
ForCATX every $1 of sales, investors are willing to pay $112.1, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Perspective Therapeutics Technicals Summary

Sell

Neutral

Buy

Perspective Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Perspective Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Perspective Therapeutics Inc.	-26.14%	-67.07%	-31.55%	-14.47%	-14.47%
Stryker Corporation	-4.86%	8.88%	24.0%	37.11%	77.64%
Boston Scientific Corp.	0.95%	18.27%	62.57%	111.2%	102.42%
Edwards Lifesciences Corp.	5.35%	-19.24%	-1.09%	-42.27%	-2.7%
Abbott Laboratories	-2.71%	9.66%	4.53%	-18.87%	32.21%
Medtronic Plc	-4.83%	2.79%	-1.07%	-21.92%	-27.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Perspective Therapeutics Inc.	NA	NA	NA	-0.84	-0.27	-0.14	NA	4.86
Stryker Corporation	39.7	39.7	2.56	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	75.26	75.26	1.65	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	29.1	29.1	6.92	2.55	0.19	0.11	NA	16.18
Abbott Laboratories	34.88	34.88	2.22	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	24.94	24.94	1.49	5.2	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Perspective Therapeutics Inc.	Buy	$219.7M	-14.47%	NA	0.0%
Stryker Corporation	Buy	$141.3B	77.64%	39.7	16.34%
Boston Scientific Corp.	Buy	$134.2B	102.42%	75.26	11.26%
Edwards Lifesciences Corp.	Buy	$44.5B	-2.7%	29.1	65.86%
Abbott Laboratories	Buy	$199.0B	32.21%	34.88	13.99%
Medtronic Plc	Buy	$104.6B	-27.8%	24.94	12.06%

About Perspective Therapeutics

the introduction of cesium-131 represents the culmination of decades of work and millions of dollars of investment. top medical centers, hospitals and clinics across the united states are now offering this breakthrough treatment for cancer patients. the word brachytherapy derives from the greek prefix brachy, meaning “short” or “close,” because the titanium capsules containing the radioisotope are implanted directly into the cancerous prostate gland. treatment of cancer using low dose radiation or “seed” brachytherapy was pioneered in the 1960’s as an effective alternative to radical prostatectomy. pioneers in brachytherapy research initially theorized about the use of cesium-131 in a titanium capsule, however scientific and economic limitations at the time prevented its development and iodine-125 emerged as an alternative. beginning in 1967, iodine-125 became the first radioisotope manufactured in a titanium capsule, or seed. while its use continues to this day, many patients and doct

Organization	Perspective Therapeutics
Employees	116
CEO	Mr. Johan M. Spoor
Industry	Miscellaneous

Management People of Perspective Therapeutics

Name	Title
Mr. Johan M. Spoor	CEO & Director
Mr. Jonathan R. Hunt	CFO and Principal Financial & Accounting Officer
Dr. Markus Puhlmann M.B.A., M.D.	Chief Medical Officer
Mr. Shane Cobb	Executive Vice President of Operations
Dr. Michael K. Schultz Ph.D.	Chief Science Officer
Ms. Annie J. Cheng	Vice President of Investor Relations
Mr. Andrew Bright	Executive Vice President of Brachytherapy
Mr. Amos Hedt BA, PGradDip	Chief Business Strategy Officer
Dr. Frances L. Johnson M.D.	Chief Innovation Officer
Mr. David Hauser Ph.D.	Senior Vice President of Clinical Operations

Important FAQs about investing in Perspective Therapeutics from India :

What is Perspective Therapeutics share price today?

Perspective Therapeutics share price today stands at $3.25, Open: $3.19 ; Previous Close: $3.14 ; High: $3.28 ; Low: $3.10 ; 52 Week High: $19.05 ; 52 Week Low: $2.70. The stock opens at $3.19, after a previous close of $3.14. The stock reached a daily high of $3.28 and a low of $3.10, with a 52-week high of $19.05 and a 52-week low of $2.70.

Can Indians buy Perspective Therapeutics shares?

Yes, Indians can invest in the Perspective Therapeutics (CATX) from India.

With INDmoney, you can buy Perspective Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Perspective Therapeutics at zero transaction cost.

How can I buy Perspective Therapeutics shares from India?

It is very easy to buy Perspective Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Perspective Therapeutics be purchased?

Yes, you can buy fractional shares of Perspective Therapeutics with INDmoney app.

What are the documents required to start investing in Perspective Therapeutics stocks?

To start investing in Perspective Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.